Alnylam

Press Releases

May 09,2019
Summary ToggleAlnylam to Webcast Presentation at Bank of America Merrill Lynch Health Care Conference 2019
PDF Version
May 01,2019
Summary ToggleAlnylam Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Period Activity
PDF Version
Apr 30,2019
Summary ToggleAlnylam Highlights Progress on Global Market Access for ONPATTRO (patisiran)
PDF Version
Apr 23,2019
Summary ToggleAlnylam to Webcast Conference Call Discussing First Quarter 2019 Financial Results
PDF Version
Apr 15,2019
Summary ToggleAlnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study
PDF Version
Apr 12,2019
Summary ToggleAlnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria
PDF Version
Apr 08,2019
Summary ToggleAlnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
PDF Version
Apr 08,2019
Summary ToggleAlnylam and Sanofi Conclude Research and Option Phase of 2014 RNAi Therapeutics Collaboration
PDF Version
Mar 27,2019
Summary ToggleAlnylam to Present Givosiran Phase 3 Data at the European Association for the Study of the Liver (EASL) International Liver Congress™
PDF Version
Mar 11,2019
Summary ToggleAlnylam Submits CTA Application for ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension in High Unmet Need Settings
PDF Version
Mar 07,2019
Summary ToggleAlnylam to Webcast Presentation at Cowen & Company 39th Annual Health Care Conference
PDF Version
Mar 06,2019
Summary ToggleAlnylam Reports Positive Topline Results from ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria
PDF Version
Feb 28,2019
Summary ToggleAlnylam Announces Recipients of First Annual Advocacy for Impact Grants Program
PDF Version
Feb 07,2019
Summary ToggleAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Recent Period Activity
PDF Version
Feb 06,2019
Summary ToggleAlnylam Announces Publication of Phase 1 Givosiran Data in The New England Journal of Medicine
PDF Version
Feb 04,2019
Summary ToggleAlnylam to Webcast Presentations at Upcoming February Investor Conferences
PDF Version
Jan 31,2019
Summary ToggleAlnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2018 Financial Results
PDF Version
Jan 21,2019
Summary ToggleAlnylam Pharmaceuticals and Medison Pharma Partner to Commercialize RNAi Therapeutics in Israel
PDF Version
Jan 14,2019
Summary ToggleAlnylam Pharmaceuticals Prices Public Offering of Common Stock
PDF Version
Jan 14,2019
Summary ToggleAlnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock
PDF Version
Displaying 21 - 40 of 1034 results
View all releases

Search

: (Common):

Price:
Change (%):
Volume:
Data as of
Copyright NASDAQ. Minimum 15 minutes delay
Learn More